Keenova Therapeutics plc 8-K

What Happened

• Keenova Therapeutics plc (through its subsidiary ST Shared Services LLC) filed an 8-K on Feb 24, 2026 disclosing a Fourth Amended and Restated Employment Agreement with Sigurdur (Siggi) Olafsson. The agreement supersedes his prior agreement (disclosed July 7, 2025) and keeps him as CEO through an Expiration Date of January 1, 2028. He is to be appointed Chair of the Board by May 14, 2026; if a successor CEO is hired before Jan 1, 2028 he will transition to Executive Chair.

Key Details

• Base salary: $1,200,000 per year (reduced by 20% if he transitions to Executive Chair before Jan 1, 2028).
• Cash bonus: target 200% of base salary and maximum 400% of base; actual payouts based on Board-determined performance metrics.
• Annual long-term incentives: 2026 grants totaling 152,722 RSUs and PSUs; beginning 2027, annual LTI grants with grant-date fair value of at least $11,500,000.
• Founders Grant: one-time RSU grant at least 2.3x the size of the second-largest Founders Grant, vesting ratably over years 1–3.
• Severance if terminated without Cause, by Executive for Good Reason, death or Disability: lump sum equal to 2.5x (annual base + target bonus), payment of prior inducement award (if unpaid) and prorated bonus, immediate vesting of certain inducement/Founders RSUs, special treatment for 2026+ LTI awards (including immediate vesting of RSUs that would vest Q1 2028 and prorated PSUs in certain Good Reason scenarios), and up to 30 months of COBRA or equivalent cash.
• Post-termination restrictions: 12-month non-solicit and 12-month non-compete during the Restricted Period, with exceptions if termination occurs on/after the Expiration Date or if terminated without Cause/by Executive for Good Reason.
• The Employment Agreement is filed as Exhibit 10.1 to the 8-K.

Why It Matters

• Leadership continuity: the agreement secures Olafsson’s leadership through Jan 1, 2028 and elevates him to Chair, which signals management continuity and concentrated executive control during this period.
• Compensation and dilution: very large equity and incentive awards (notably the $11.5M+ annual LTI target starting 2027 and the 2026 RSU/PSU grant) align the CEO with company performance but will increase share-based compensation expense and may dilute shareholders.
• Potential cash and equity liabilities: the detailed severance and vesting provisions could result in material cash payments and accelerated equity vesting if the CEO departs under specified circumstances.
• No financial results disclosed: this filing concerns governance and executive compensation, not quarterly earnings or revenue; investors should watch for related governance changes or future filings with more financial detail.